Drug Profile
Research programme: anti-CD20 monoclonal antibodies - Biocad
Alternative Names: Anti-CD20 MAB - BiocadLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Biocad
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in Russia (Parenteral)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Russia (Parenteral)
- 16 Jul 2020 Anti-CD20 monoclonal antibody programme is still in preclinical development for Cancer and Autoimmune disorders (Biocad pipeline, July 2020)